EGFR and lung cancer: In the multivariate analysis of PFS, the baseline PDC response was independently associated with a better PFS in untreated patients with EGFR/ALK-positive lung cancer (hazard ratio: 0.20, 95% CI: 0.07–0.0.60, p = 0.004).